{"id":"live-attenuated-japanese-encephalitis-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108939","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a live but attenuated (weakened) strain of Japanese encephalitis virus that can replicate in vaccinated individuals but has reduced pathogenicity. This triggers both cellular and humoral immune responses, including the production of neutralizing antibodies and T-cell immunity against viral antigens. The immune memory generated provides protection against subsequent exposure to wild-type Japanese encephalitis virus.","oneSentence":"This live attenuated vaccine stimulates immune responses against Japanese encephalitis virus by introducing a weakened form of the virus that replicates but does not cause disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:04.568Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis"}]},"trialDetails":[{"nctId":"NCT03920111","phase":"NA","title":"Flavivirus Cross-priming Potential of IMOJEV","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2021-04-16","conditions":"Japanese Encephalitis","enrollment":19},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT06027801","phase":"NA","title":"Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-09-06","conditions":"Iron Deficiency Anemia","enrollment":150},{"nctId":"NCT05568953","phase":"PHASE2","title":"An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2022-09-28","conditions":"Infectious Disease, Yellow Fever, Japanese Encephalitis","enrollment":70},{"nctId":"NCT04817917","phase":"PHASE4","title":"Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-03-01","conditions":"Japanese Encephalitis, Vaccine Preventable Disease, Vaccine Reaction","enrollment":712},{"nctId":"NCT02933710","phase":"","title":"Postmarketing Surveillance Study for IMOJEV® in Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-21","conditions":"Japanese Encephalitis","enrollment":50},{"nctId":"NCT02492165","phase":"PHASE3","title":"Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-06","conditions":"Japanese Encephalitis","enrollment":250},{"nctId":"NCT01900444","phase":"PHASE3","title":"Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-07-11","conditions":"Japanese Encephalitis","enrollment":119},{"nctId":"NCT04111432","phase":"PHASE4","title":"Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-26","conditions":"Hand, Foot and Mouth Disease","enrollment":372},{"nctId":"NCT02514746","phase":"PHASE4","title":"Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose","status":"COMPLETED","sponsor":"PATH","startDate":"2015-07-30","conditions":"Encephalitis, Japanese","enrollment":561},{"nctId":"NCT02880865","phase":"PHASE4","title":"Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2016-10-13","conditions":"Encephalitis, Japanese, Measles, Mumps","enrollment":628},{"nctId":"NCT00463476","phase":"PHASE4","title":"Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2007-07-09","conditions":"Japanese Encephalitis","enrollment":305},{"nctId":"NCT00249769","phase":"PHASE3","title":"Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2005-11-21","conditions":"Encephalitis, Japanese B","enrollment":600},{"nctId":"NCT01656200","phase":"PHASE4","title":"A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2","status":"COMPLETED","sponsor":"Indian Institute of Science","startDate":"2012-05","conditions":"Japanese Encephalitis, Japanese Encephalitis Vaccine","enrollment":17},{"nctId":"NCT00463684","phase":"PHASE4","title":"Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age","status":"COMPLETED","sponsor":"PATH","startDate":"2007-07-07","conditions":"Japanese Encephalitis","enrollment":278},{"nctId":"NCT01567865","phase":"PHASE4","title":"Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-05","conditions":"Japanese Encephalitis","enrollment":818},{"nctId":"NCT03296410","phase":"PHASE4","title":"The Phase IVd of Inactivated Enterovirus 71 Vaccine","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2017-09-14","conditions":"Hand, Foot and Mouth Disease (HFMD)","enrollment":1220},{"nctId":"NCT02526550","phase":"PHASE4","title":"Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2014-06","conditions":"Encephalitis","enrollment":50},{"nctId":"NCT01635816","phase":"PHASE4","title":"Immunogenicity of SA 14-14-2 JE Vaccine","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2012-05","conditions":"Healthy Infants","enrollment":1000},{"nctId":"NCT01981967","phase":"PHASE4","title":"Post-licensure Safety Study of IMOJEV® in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-11","conditions":"Japanese Encephalitis","enrollment":10000},{"nctId":"NCT02602652","phase":"NA","title":"Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2013-12","conditions":"Japanese Encephalitis","enrollment":50},{"nctId":"NCT00412516","phase":"PHASE3","title":"Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2006-12","conditions":"Encephalitis, Japanese B","enrollment":519},{"nctId":"NCT01188343","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Japanese Encephalitis, Measles, Mumps","enrollment":542},{"nctId":"NCT01396512","phase":"PHASE3","title":"Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07","conditions":"Japanese Encephalitis, Japanese Encephalitis Virus Disease","enrollment":274},{"nctId":"NCT00384670","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2003-08","conditions":"Dengue Fever","enrollment":7},{"nctId":"NCT00314132","phase":"PHASE3","title":"Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Encephalitis, Japanese Encephalitis","enrollment":2004},{"nctId":"NCT00981630","phase":"PHASE2","title":"Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Japanese Encephalitis","enrollment":128},{"nctId":"NCT00982137","phase":"PHASE2","title":"Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Japanese Encephalitis, Yellow Fever","enrollment":108},{"nctId":"NCT00319592","phase":"PHASE2","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Japanese Encephalitis","enrollment":60},{"nctId":"NCT00981175","phase":"PHASE2","title":"A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-04","conditions":"Encephalitis, Japanese Encephalitis","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"live attenuated Japanese encephalitis vaccine","genericName":"live attenuated Japanese encephalitis vaccine","companyName":"Chinese Academy of Medical Sciences","companyId":"chinese-academy-of-medical-sciences","modality":"Biologic","firstApprovalDate":"","aiSummary":"This live attenuated vaccine stimulates immune responses against Japanese encephalitis virus by introducing a weakened form of the virus that replicates but does not cause disease. Used for Prevention of Japanese encephalitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}